Pliant Therapeutics (NASDAQ: PLRX) CFO share sale for tax withholding

Q: What insider transaction did Pliant Therapeutics (PLRX) report in this Form 4?

The filing reports that Chief Financial Officer Keith Lamont Cummings had 24,002 shares of Pliant Therapeutics Common Stock sold on his behalf on January 20, 2026 , under a nondiscretionary plan.

Q: At what price were the Pliant Therapeutics (PLRX) shares sold by the CFO?

The Form 4 lists a weighted average sale price of $1.28 per share . The broker sold shares within a range of $1.245 to $1.33 over January 20–22, 2026.

Q: Why were Pliant Therapeutics (PLRX) shares sold for CFO Keith Cummings?

The filing explains that the sale was a nondiscretionary transaction under a Rule 10b5-1 plan , executed to satisfy withholding tax liabilities related to the vesting of previously granted restricted stock units.

Q: Does the Form 4 mention any shares acquired through an employee stock purchase plan at Pliant Therapeutics (PLRX)?

Yes. The footnotes state that the reported holdings include 1,958 shares of Common Stock acquired by the CFO through an Employee Stock Purchase Plan program.

Q: Was the CFO’s Pliant Therapeutics (PLRX) sale discretionary or pre-planned?

The filing describes the transaction as a nondiscretionary sale by the plan on behalf of the reporting person, intended to comply with Rule 10b5-1 and cover tax withholding.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Pliant Therapeutics’ Chief Financial Officer Keith Lamont Cummings reported an automatic sale of company stock. On January 20, 2026, a plan sold 24,002 shares of Common Stock on his behalf at a weighted average price of $1.28 per share, as part of a nondiscretionary Rule 10b5-1 arrangement.

The shares were sold by a broker over a price range of $1.245 to $1.33 between January 20 and January 22, 2026, to cover withholding taxes related to the vesting of previously granted restricted stock units. After this transaction, Cummings beneficially owned 297,214 shares of Pliant Therapeutics Common Stock, which include 1,958 shares acquired through an employee stock purchase plan.

Insider Trade Summary

Net Seller: 24,002 shares ($30,723)

Net Sell 1 txn

Insider Cummings Keith Lamont

Role Chief Financial Officer

Sold 24,002 shs ($31K)

Type	Security	Shares	Price	Value
Sale	Common Stock	24,002	$1.28	$31K

Holdings After Transaction: Common Stock — 297,214 shares (Direct)

Footnotes (1)

Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Includes 1,958 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.

Form 4 Insider Transactions: What Each Field Means →

01/22/2026 - 09:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cummings Keith Lamont

(Last)

(First)

(Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/20/2026		S		24,002	D	$1.28⁽¹⁾	297,214⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

2. Includes 1,958 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Pliant Therapeutics (PLRX) report in this Form 4?

The filing reports that Chief Financial Officer Keith Lamont Cummings had 24,002 shares of Pliant Therapeutics Common Stock sold on his behalf on January 20, 2026, under a nondiscretionary plan.

At what price were the Pliant Therapeutics (PLRX) shares sold by the CFO?

The Form 4 lists a weighted average sale price of $1.28 per share. The broker sold shares within a range of $1.245 to $1.33 over January 20–22, 2026.

Why were Pliant Therapeutics (PLRX) shares sold for CFO Keith Cummings?

The filing explains that the sale was a nondiscretionary transaction under a Rule 10b5-1 plan, executed to satisfy withholding tax liabilities related to the vesting of previously granted restricted stock units.

How many Pliant Therapeutics (PLRX) shares does the CFO own after the reported sale?

After the reported transaction, Chief Financial Officer Keith Lamont Cummings beneficially owned 297,214 shares of Pliant Therapeutics Common Stock.

Does the Form 4 mention any shares acquired through an employee stock purchase plan at Pliant Therapeutics (PLRX)?

Yes. The footnotes state that the reported holdings include 1,958 shares of Common Stock acquired by the CFO through an Employee Stock Purchase Plan program.

Was the CFO’s Pliant Therapeutics (PLRX) sale discretionary or pre-planned?

The filing describes the transaction as a nondiscretionary sale by the plan on behalf of the reporting person, intended to comply with Rule 10b5-1 and cover tax withholding.